AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 285: E566-E576, 2003. First published May 7, 2003; doi:10.1152/ajpendo.00148.2003
0193-1849/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
285/3/E566    most recent
00148.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Folny, V.
Right arrow Articles by Serradeil-Le Gal, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Folny, V.
Right arrow Articles by Serradeil-Le Gal, C.

Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas

Viviane Folny,1 Danielle Raufaste,1 Ludovit Lukovic,2 Brigitte Pouzet,1 Pierrick Rochard,1 Marc Pascal,1 and Claudine Serradeil-Le Gal1

Exploratory Research Department Sanofi-Synthélabo Recherche 131036 Toulouse and 267080 Strasbourg, France

Submitted 7 April 2003 ; accepted in final form 29 April 2003

Vasopressin (AVP) receptors present in In-R1-G9 cells, a hamster glucagon-secreting {alpha}-pancreatic cell line, were characterized using SSR-149415, a selective nonpeptide V1b receptor antagonist, and reference AVP compounds. Binding experiments, using [3H]AVP as a ligand, identified a single population of high-affinity binding sites. SSR-149415 competitively inhibited this binding and exhibited nanomolar and stereospecific affinity for these sites. The affinity of various AVP/oxytocin ligands confirmed a V1b binding profile. In functional studies, AVP was a potent stimulant in inducing intracellular Ca2+ increase, glucagon secretion, and cell proliferation. These effects were fully antagonized by SSR-149415 with a nanomolar potency, whereas its diasteroisomer as well as two selective V1a and V2 receptor antagonists were much less potent. Additionally, the order of potency of AVP agonists and antagonists was in agreement with V1b-mediated effects. By RT-PCR, we confirmed the presence of V1b receptor mRNA in both In-R1-G9 cells and in human pancreas. The distribution pattern of V1b receptors investigated in human pancreas by immunohistochemistry showed strong labeling in islets of Langerhans, and colocalization studies indicated that this receptor was expressed in {alpha}-glucagon, {beta}-insulin, and somatostatin pancreatic cells. Thus, in In-R1-G9 cells, AVP mediates intracellular Ca2+ increase, glucagon secretion, and cell proliferation by activating V1b receptors, and these effects are potently antagonized by SSR-149415. Moreover, the presence of V1b receptors also found in human Langerhans islets could suggest hormonal control of AVP in human pancreas.

arginine vasopressin V1b receptors; glucagon; SSR-149415



Address for reprint requests and other correspondence: C. Serradeil-Le Gal, Sanofi-Synthélabo Recherche, Exploratory Research Dept., 195 route d'Espagne, 31036 Toulouse cedex, France (E-mail: claudine.serradeil{at}sanofi-synthelabo.com.




This article has been cited by other articles:


Home page
J EndocrinolHome page
A.-M. O'Carroll, G. M Howell, E. M Roberts, and S. J Lolait
Vasopressin potentiates corticotropin-releasing hormone-induced insulin release from mouse pancreatic {beta}-cells
J. Endocrinol., May 1, 2008; 197(2): 231 - 239.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
Y. Fujiwara, M. Hiroyama, A. Sanbe, T. Aoyagi, J.-i. Birumachi, J. Yamauchi, G. Tsujimoto, and A. Tanoue
Insulin hypersensitivity in mice lacking the V1b vasopressin receptor
J. Physiol., October 1, 2007; 584(1): 235 - 244.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. S.-L. Gal, D. Raufaste, S. Derick, J. Blankenstein, J. Allen, B. Pouzet, M. Pascal, J. Wagnon, and M. A. Ventura
Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R938 - R949.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
W. Shi, N. Cui, Y. Shi, X. Zhang, Y. Yang, and C. Jiang
Arginine vasopressin inhibits Kir6.1/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R191 - R199.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
Y. Fujiwara, M. Hiroyama, A. Sanbe, J. Yamauchi, G. Tsujimoto, and A. Tanoue
Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice
J. Endocrinol., February 1, 2007; 192(2): 361 - 369.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.